GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Procaps Group SA (OTCPK:PRCWF) » Definitions » Debt-to-Asset

PRCWF (Procaps Group) Debt-to-Asset : 0.58 (As of Sep. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Procaps Group Debt-to-Asset?

Procaps Group's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $69.24 Mil. Procaps Group's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $220.68 Mil. Procaps Group's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Sep. 2023 was $498.55 Mil. Procaps Group's debt to asset for the quarter that ended in Sep. 2023 was 0.58.


Procaps Group Debt-to-Asset Historical Data

The historical data trend for Procaps Group's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Procaps Group Debt-to-Asset Chart

Procaps Group Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Debt-to-Asset
1.25 1.26 0.55 0.62

Procaps Group Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.54 0.62 0.65 0.59 0.58

Competitive Comparison of Procaps Group's Debt-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Procaps Group's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Procaps Group's Debt-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Procaps Group's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Procaps Group's Debt-to-Asset falls into.


;
;

Procaps Group Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Procaps Group's Debt-to-Asset for the fiscal year that ended in Dec. 2022 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(257.525 + 28.41) / 460.187
=0.62

Procaps Group's Debt-to-Asset for the quarter that ended in Sep. 2023 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(69.238 + 220.682) / 498.554
=0.58

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Procaps Group  (OTCPK:PRCWF) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Procaps Group Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Procaps Group's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Procaps Group Business Description

Traded in Other Exchanges
N/A
Address
9 Rue de Bitbourg, Luxembourg, LUX, L-1273
Procaps Group SA is a developer of pharmaceutical and nutraceutical solutions, medicines, and hospital supplies. It develops, manufactures, and markets over-the-counter (OTC) and prescription drugs, nutritional supplements, and high-potency clinical solutions. The company's segment includes NextGel; Procaps Colombia; CAN; CASAND and Diabetrics. It generates maximum revenue from the Procaps Colombia segment.